Listen
EXELON
-
Opinions on drugs -
Posted on
Aug 01 2008
- Updated on
Jan 12 2010
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication of “Symptomatic Treatment of Mild to Moderately Severe Forms of Dementia in Patients with Idiopathic Parkinson’s Disease.”
-
Clinical Benefit
| Moderate |
The actual benefit achieved with this proprietary medicinal product in this indication is moderate. |
Clinical Added Value
| minor |
Given the modest benefit observed and the risk of by no means negligible adverse reactions, Exelon provides a minor improvement in actual benefit (IAB IV) to patients with mild to moderately severe dementia associated with idiopathic Parkinson’s disease. The Commission notes that patients with visual hallucinations may particularly benefit from rivastigmine. |
Contact Us
Évaluation des médicaments
